Cross-Neutralization of Distant Coronaviruses Strongly Correlates with Spike S2-Specific Antibodies from Immunocompetent and Immunocompromised Vaccinated SARS-CoV-2-Infected Patients
<b>Background/Objectives</b>: Despite the lifting of the COVID-19 public health emergency, SARS-CoV-2 infections continue to be recorded worldwide. The continued prevalence of infection has been attributed to the ability of the virus to evade host immune responses, including neutralizing antibody-derived immunity. The vast majority of antibody escape mutations has been associated with the S1 subunit of the spike protein. The other region of the spike, the S2 subunit, is the most conserved region amongst coronaviruses. We hypothesized that S2-specific antibody levels are modest in vaccinated and SARS-CoV-2-infected patients, resulting in suboptimal neutralization of distant coronaviruses. <b>Methods</b>: Here, we analyzed S1- and S2-specific antibody levels in SARS-CoV-2-infected individuals, including a mixed cohort of those with and without immunosuppression and prior vaccination. <b>Results</b>: We found that S2-specific antibody responses were generally lower than S1-specific antibody responses. Intriguingly, Omicron-S1-specific antibody levels were higher than Wuhan-S1-specific antibody levels despite all vaccinated participants having received Wuhan-spike-based immunogens. This emphasizes the importance of the infecting variant and vaccine immunogen in the production of spike-targeting antibodies and associated hybrid immunity. Although S1-specific antibody levels were generally higher than their S2-specific counterparts, the correlation between neutralization and binding antibody levels was mostly higher in S2- compared with S1-specific responses. <b>Conclusions</b>: We conclude that S2-based immunogens are suitable for the induction of antibody-based immunity against novel SARS-CoV-2 variants but also against more distant coronaviruses, which would support a better protection for the immunocompromised as well as other vulnerable populations.
Authors
- Mark Jacob Siedner (ORCID: https://orcid.org/0000-0003-3506-842X)
- Rinki Deo
- Zachary S. Wallace (ORCID: https://orcid.org/0000-0003-4708-7038)
- Jeffrey A. Sparks (ORCID: https://orcid.org/0000-0002-5556-4618)
- Andrew Alexandrescu
- Jacob E. Lemieux (ORCID: https://orcid.org/0000-0002-2758-4005)
- S. Patel
- Jonathan Z. Li (ORCID: https://orcid.org/0000-0001-9914-9662)
- Ismaël Fofana (ORCID: https://orcid.org/0000-0001-6384-2836)
- Jeffrey M. DaCosta (ORCID: https://orcid.org/0000-0002-8590-2083)
- Amy K. Barczak (ORCID: https://orcid.org/0000-0003-3806-2381)
- Andrew S. Joyal
- Julie Boucau (ORCID: https://orcid.org/0000-0001-6731-7238)
- Joseph Vecchio (ORCID: https://orcid.org/0009-0004-4473-5428)
- Zahra Reynolds (ORCID: https://orcid.org/0000-0003-0668-6798)
- Manish C. Choudhary (ORCID: https://orcid.org/0000-0002-3192-7840)
- Mamadou Barry (ORCID: https://orcid.org/0009-0005-1458-2528)
- Tammy D. Vyas
- Jatin M. Vyas (ORCID: https://orcid.org/0000-0002-9985-9565)
- Owen T. Glover
- Yijia Li (ORCID: https://orcid.org/0000-0001-5300-0571)
- Eliza Passell
- Emory Abar
- Gregory E. Edelstein
- Karry Su
- Trevor J. Tamura
- Dessie Tien
- Brooke M. Leeman
- Patricia J. Botros
- Joanna Folta
- Dhiman Shahid
- Anya I. Rocque
Institutions
- Boston College (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Ragon Institute of MGH, MIT and Harvard (US)
Publication Details
- Journal
- Vaccines
- Published
- 2025-09-04
- DOI
- https://doi.org/10.3390/vaccines13090949
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Brigham and Women's Hospital
- Massachusetts General Hospital
- Gordon and Llura Gund Foundation
- National Institutes of Health
- National Institute of Arthritis and Musculoskeletal and Skin Diseases